Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer

[1]  N. Christakis,et al.  Prognostic factors in advanced cancer patients: evidence-based clinical recommendations--a study by the Steering Committee of the European Association for Palliative Care. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  C. McArdle,et al.  A prospective longitudinal study of performance status, an inflammation-based score (GPS) and survival in patients with inoperable non-small-cell lung cancer , 2005, British Journal of Cancer.

[3]  M. Piccart,et al.  Facts and controversies in systemic treatment of metastatic breast cancer. , 2004, The oncologist.

[4]  C. McArdle,et al.  Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer , 2004, British Journal of Cancer.

[5]  C. McArdle,et al.  Score Based on Hypoalbuminemia and Elevated C-Reactive Protein Predicts Survival in Patients With Advanced Gastrointestinal Cancer , 2004, Nutrition and cancer.

[6]  Ana Lluch,et al.  Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients , 1999, Breast Cancer Research and Treatment.

[7]  A. Lipton,et al.  Metastatic breast cancer: overview of treatment. , 2003, Clinical orthopaedics and related research.

[8]  D C McMillan,et al.  Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer , 2003, British Journal of Cancer.

[9]  Paul Glare,et al.  A systematic review of physicians' survival predictions in terminally ill cancer patients , 2003, BMJ : British Medical Journal.

[10]  K. Malone,et al.  Differences in breast cancer stage, treatment, and survival by race and ethnicity. , 2003, Archives of internal medicine.

[11]  I. Simera,et al.  Short versus long duration infusions of paclitaxel for any adenocarcinoma. , 2003, The Cochrane database of systematic reviews.

[12]  N. Tsavaris,et al.  Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes , 2002, British Journal of Cancer.

[13]  F. Mahmoud,et al.  The role of C-reactive protein as a prognostic indicator in advanced cancer , 2002, Current oncology reports.

[14]  Y Ohno,et al.  Prognostic value of performance status assessed by patients themselves, nurses, and oncologists in advanced non-small cell lung cancer , 2001, British Journal of Cancer.

[15]  M. Sant.  Differences in stage and therapy for breast cancer across Europe , 2001, International journal of cancer.

[16]  J. Kurebayashi.  Regulation of interleukin-6 secretion from breast cancer cells and its clinical implications , 2000, Breast cancer.

[17]  N. Christakis,et al.  Extent and determinants of error in doctors' prognoses in terminally ill patients: prospective cohort study , 2000, BMJ : British Medical Journal.

[18]  Guo‐Jun Zhang,et al.  Serum interleukin-6 levels correlate to tumor progression and prognosis in metastatic breast carcinoma. , 1999, Anticancer research.

[19]  I. Kushner,et al.  Acute-phase proteins and other systemic responses to inflammation. , 1999, The New England journal of medicine.

[20]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[21]  Y. Nomura.  Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy. , 1998, International journal of oncology.

[22]  C. McArdle,et al.  Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients. , 1998, Nutrition and cancer.

[23]  R. Blamey,et al.  Pre-treatment serum levels of tumour markers in metastatic breast cancer: a prospective assessment of their role in predicting response to therapy and survival. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.